Management and Board of Directors

Professor Ashley Woodcock serves as Professor of Respiratory Medicine at the University of Manchester and the Clinical Director at the North West Lung Centre, University Hospital of South Manchester. With an illustrious career beginning as an NHS Consultant Physician in Manchester in 1985, he has substantially contributed to the field through roles such as Chairman of the Clinical Assembly of the European Respiratory Society and President of the British Thoracic Society. His notable accolades include sharing the 2007 Nobel Peace Prize with the International Panel for Climate Change and Al Gore, receiving an OBE in 2006 for services to the Environment, and being named a Fellow of both the Academy of Medical Sciences and the European Respiratory Society. Professor Woodcock has co-authored over 300 original publications and has pioneered significant research initiatives including the Manchester Asthma and Allergy Study. His recent work includes leading a groundbreaking cough research group and overseeing the largest Respiratory Unit in the UK at the North West Lung Centre, which offers advanced, specialized care across all subspecialties of Respiratory Medicine.

Before joining Axalbion, Olivier worked as Research Project Manager in academia as well as service provider and consultant for biomedical startups. During his 15+ years' experience, he investigated the role of receptors and ion channels in pathological and physiological conditions as well as their regulation and pharmacology. He developed a strong expertise in the fields of pain, inflammation and peripheral neuropathies. Olivier received his master’s degree in Molecular Neuroscience from Montpellier 2 University and its doctorate in Neuroscience from Lausanne University. He completed his curriculum with a PMI project management professional (PMP)® certification.

Jonathan was biotech equity research analyst at Credit Suisse, (no.1 ranked team) and Evolution. Prior to joining Stifel to set up the European Life Sciences team, he spent six years in Corporate Finance at Nomura Code. IPO experience includes NicOx, GPC Biotech, Actelion, Entelos and Carmat. Other transactions include fund-raisings for Vernalis, Summit, Medgenics and Glide Pharma as well as sale of CBT to Proximagen. During his time at Stifel he undertook numerous transactions, in the UK, Europe and the US, including deals for HCM, ReNeuron, Calliditas, Ergomed, Nanobiotix and Renalytx. He is more recently been CFO at Sitryx and is currently CFO at Biofidelity and Axalbion. Jonathan is a qualified medical doctor.